Comparative Pharmacology
Head-to-head clinical analysis: IMPOYZ versus WAYRILZ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IMPOYZ versus WAYRILZ.
IMPOYZ vs WAYRILZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
IMPOYZ is a monoclonal antibody that binds to and inhibits the activity of interleukin-23 (IL-23), a cytokine involved in inflammatory and immune responses. By blocking IL-23, it reduces the production of pro-inflammatory cytokines and attenuates the inflammatory cascade.
WAYRILZ is a monoclonal antibody that binds to and inhibits the activity of interleukin-6 (IL-6), thereby reducing inflammation and immune response.
100 mg orally twice daily
WAYRILZ 500 mg orally twice daily without regard to meals.
None Documented
None Documented
Terminal elimination half-life 6–8 hours in adults with normal renal function; prolonged to 15–30 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life is 12 hours, supporting twice-daily dosing in patients with normal renal function.
Primarily renal (70–80% as unchanged drug via glomerular filtration and tubular secretion); biliary/fecal (15–20%) with minor hepatic metabolism.
Renal elimination of unchanged drug accounts for 85% of total clearance; fecal/biliary elimination accounts for 12%, with the remainder via metabolic inactivation.
Category C
Category C
Unknown
Unknown